Collection
Role of RNA Modifications in chronic non-communicable diseases
Chronic non-communicable diseases (CNCD) are main human health conditions that are persistent or otherwise long-lasting in their effects or a disease that comes with time. CNCD include neoplasms, cardiovascular diseases, diabetes, chronic respiratory disease, diabetes, etc. In addition, CNCD has multifactorial aetiologies that are considered to be caused by the interaction of environmental risk factors with multiple predisposing genes.
RNA plays essential roles in not only translating nucleic acids into proteins, but also in gene regulation, environmental interactions, and many human diseases. RNA modifications can be added or removed by a variety of enzymes that catalyze the necessary reactions, and these modifications play roles in essential molecular mechanisms. The prevalent modifications on mRNA include N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 5-hydroxymethylcytosine (hm5C), pseudouridine (Ψ), inosine (I), uridine (U), ribose-methylation (2'-O-Me), etc. Most of these modifications contribute to pre-mRNA splicing, nuclear export, transcript stability, and translation initiation in eukaryotic cells. By participating in various physiological processes, RNA modifications have regulatory roles in the pathogenesis of CNCD. However, the related studies are still few, and the role of RNA modifications in CNCD remains to be clarified.
This Topical Collection welcomes original and review articles, as well as systematic reviews. Potential topics may include:
1) Molecular mechanisms of epigenetic modifications (e.g., m6A, m1A, m5C, (hm5C, Ψ, I, U, 2'-O-Me) regulating oxidative stress
2) RNA modification-based therapy in CNCD.
3) Discovery of novel RNA modification types involved in CNCD.
4) Identification of novel RNA modification targets and signaling pathways.
5) Studies In vivo and in vitro focused on the RNA modification mechanism of small molecular compounds involved in CNCD.
6) The role of RNA modifications in cellular senescence-related CNCD.
Editors
-
Elisa Giovannetti
Dr. Elisa Giovannetti is associate professor and PI at VU University Medical Center, Amsterdam, The Netherlands. Her research activities are devoted to preclinical/translational studies on molecular mechanisms underlying drugs resistance, especially for pancreatic and lung cancer.
Based on (epi)genetic and proteomics biomarkers, her research contributed to the molecular characterization of pancreatic cancers, to identify more effective patient-tailored treatments. She is Chair of the Pharmacology and Molecular Mechanisms group (PAMM) of the EORTC, and member of the Editorial Boards of Crit Rev Oncol Hematol and Cell Oncol
-
Tian Li
Dr. Tian Li is a researcher at the School of Basic Medicine, Fourth Military Medical University, Xi'an, China, devoted to research on the mechanisms of and pharmacological strategies for chronic diseases. Dr. Li has published over 140 papers in journals including Cytokine Growth Factor Rev, Semin Cancer Biol, EClinicalMedicine, Drugs, J Pineal Res, Pharmacol Res, Ageing Res Rev, Cell Mol Life Sci, Neurology, etc. Owing to Li’s contributions to the research landscape, he has acted as Guest/Routine Editor (present and past) for more than 20 SCI-indexed journals including Cytokine Growth Factor Rev and Semin Cancer Biol.
Articles (4 in this collection)
-
-
-
IGF2BP3-mediated enhanced stability of MYLK represses MSC adipogenesis and alleviates obesity and insulin resistance in HFD mice
Authors (first, second and last of 5)
-
Calcium-sensing receptor and NF-κB pathways in TN breast cancer contribute to cancer-induced cardiomyocyte damage via activating neutrophil extracellular traps formation
Authors (first, second and last of 15)
